UNCONVENTIONAL PATTERN OF RESPONSE IN A METASTATIC MELANOMA PATIENT TREATED WITH IPILIMUMAB.

We present the case of a 74 year old man who achieved a complete response for hepatic and cutaneous metastasis and stabilization of his lymph node metastases after treatment with ipilimumab at 10 mg/Kg. The patient was diagnosed with right foot cutaneous melanoma in February 2004. In October the patient became metastatic and he underwent three different lines of traditional chemotherapy (Fotemustine, Dacarbazin and Carboplatin with Thalidomide) but each time a progression of the disease was noted. Consequently, the patient was enrolled in Protocol CA180008 and treated with ipilimumab 10mg/Kg every 3 weeks for 4 cycles. Ipilimumab has been established as a drug able to induce long-lasting responses, and has been approved for patients with metastatic melanoma in first- and second-line treatment by the FDA and in second-line treatment by the EMA